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Neuraminidase inhibitors (NAIs) oseltamivir
and zanamivir are currently the only effective
antiviral drugs available worldwide for the
management of influenza. The potential devel-
opment of resistance is continually threatening
their use, rationalizing and highlighting the
need for a close and sustained evaluation of
virus susceptibility. This study aimed to ana-
lyze and characterize the phenotypic and geno-
typic NAIs susceptibility profiles of A(H1N1)
pdm09 viruses circulating in Portugal from
2009 to 2010/2011. A total of 144 cases of
A(H1N1)pdm09 virus infection from community
and hospitalized patients were studied, includ-
ing three suspected cases of clinical resistance
to oseltamivir. Oseltamivir resistance was con-
firmed for two of the suspected cases. Neur-
aminidase (NA) H275Y resistant marker was
found in viruses from both cases but for one it
was only present in 26.2% of virus population,
raising questions about the minimal percent-
age of resistant virus that should be consid-
ered relevant. Cross-decreased susceptibility to
oseltamivir and zanamivir (2–4 IC50 fold-
change) was detected on viruses from two
potentially linked community patients from
2009. Both viruses harbored the NA I223V
mutation. NA Y155H mutation was found in 18
statistical non-outlier viruses from 2009, having
no impact on virus susceptibility. The muta-
tions at NA N369K and V241I may have con-
tributed to the significantly higher baseline IC50
value obtained to oseltamivir for 2010/2011
viruses, compared to viruses from the pan-
demic period. These results may contribute to
a better understanding of the relationship
between phenotype and genotype, which is
currently challenging, and to the global assess-
ment of A(H1N1)pdm09 virus susceptibility
profile and baseline level to NAIs. J. Med.
Virol. 87:45–56, 2015.
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INTRODUCTION
A(H1N1)2009 pandemic was the first influenza
pandemic having the assistance of an extensive
preparedness and response planning. Advance stock-
piling of antiviral drugs was one of the key measures
recommend by World Health Organization (WHO),
and neuraminidase inhibitors (NAIs), in particular
oseltamivir, were the antiviral drugs of choice for
many developed countries [WHO, 2005, 2009a; Meijer
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et al., 2007; Oshitani et al., 2008]. Portugal stockpiled
a large amount of oseltamivir phosphate (enough for
2.51 million treatments and 100,000 prophylactic
schemes) and a small quantity of zanamivir (enough
for 42 treatments). This national stockpile was re-
leased on April 24, 2009, immediately after the
activation of the National Contingency Plan due to
A(H1N1)pdm09 virus emergence [DGS, 2010]. Na-
tional progression from the containment to mitigation
pandemic stage on 21st August and availability of
the pandemic vaccine on 26th October required
timely national updates on the recommendations for
antiviral drug use during 2009 [DGS, 2010].
NAIs were an appropriate choice for A(H1N1)2009
pandemic prevention and control. This new variant of
the Orthomyxoviridae family, Influenzavirus A genus,
exhibited natural resistance to M2 protein inhibitors
and clinical effectiveness of NAIs was reported in
observational studies carried out during the pandem-
ic period [CDC, 2009; Dominguez-Cherit et al., 2009;
Jain et al., 2009; Pada and Tambyah, 2011]. Also, the
emergence of resistant variants was only detected for
oseltamivir and limited to sporadic events, largely in
association with drug use and patients with an
immunocompromised condition [WHO, 2011a]. The
first case of oseltamivir resistance was reported by
Denmark Health Authorities 3 months after the emer-
gence of the A(H1N1)2009 variant, demonstrating the
importance of national capability for the rapid detec-
tion of resistant variants [ECDC, 2009]. Since then and
until October 5, 2011, a further 604 cases of oseltami-
vir resistance were detected globally, all harboring the
neuraminidase (NA) H275Y mutation. Person-to-person
transmission of oseltamivir-resistant virus was identi-
fied during the pandemic period but only in three
limited clusters, variable in size, timing and location
[WHO, 2010, 2011a]. During the following 2010/2011
season, national surveillance activities carried out at
the United Kingdom, Japan, and United States re-
ported an increase in the proportion of A(H1N1)pdm09
oseltamivir-resistant virus with no known exposure to
the drug, potentially indicating a low-level transmis-
sion of resistant virus in the community [Lackenby
et al., 2011; WHO, 2011a]. This was confirmed recent-
ly, by the identification of a community cluster of 6
A(H1N1)pdm09 oseltamivir and peramivir-resistant
viruses (H275Y) with no known association to drug use
during the end of 2013 in Japan [Takashita et al.,
2014]. Regarding zanamivir, only one case of reduced
susceptibility was identified to date, in a virus harbor-
ing NA I223R mutation collected from an immunocom-
promised child [WHO, 2011a].
The aim of this study was to analyze and charac-
terize the NAIs susceptibility profiles of influenza
A(H1N1)pdm09 viruses circulating in Portugal, from
the 2009 pandemic period to the 2010/2011 winter
season and in both community and hospital settings,
to NAIs (oseltamivir and zanamivir). Suspected
cases of clinical resistance development were also
studied.
MATERIALS AND METHODS
Clinical Specimens and Virus Strains
Clinical specimens from the upper respiratory tract
of patients positive for influenza A(H1N1)pdm09
virus infection were used. Specimens were provided
by two national reference hospitals—Hospital de
Curry Cabral (HCC) and Hospital Dona Estefaˆnia
(HDE) (Lisbon, Portugal). Specimen collection was
performed in hospitalized and in community patients
attending the hospital emergency unit, from the 2009
pandemic period (June 2009–January 2010) to the
2010/2011 winter season (January–March 2011).
A total of 216 cases of influenza A(H1N1)pdm09
virus infection, 163 from the pandemic period and 53
from 2010/2011, were selected for study. This in-
cludes three suspected cases of clinical resistance
identified by the hospital clinicians during 2010/2011
in non-related hospitalized patients that failed to
respond to oseltamivir treatment (positive for influen-
za after >10 days of therapy), independently of the
timing between symptom onset and initiation of
therapy (< or >48hr) (Table I). Clinical specimens
from these three suspected cases were directly tested
for the presence of the NA H275Y oseltamivir-resistant
marker. These and all the other 213 specimens from
the remaining selected cases underwent viral isolation
in MDCK-SIAT1 cells. A total of 142 A(H1N1)pdm09
virus strains were isolated successfully, 116 from the
pandemic period and 26 from 2010/2011, and evaluated
further for phenotypic antiviral drug susceptibility,
using mainly a second or third cell passage isolate.
This includes the virus strain isolated from suspected
case 2 (A/Portugal/03/2011), that was the only sus-
pected case for which viral isolation was successful
(Table I). Fifty of the 142 virus strains tested pheno-
typically, 44 from the pandemic period and 6 from
2010/2011, were evaluated for genotypic antiviral drug
susceptibility by NA and hemagglutinin (HA) sequenc-
ing. This comprised all virus strains identified as
statistical outliers in the phenotypic evaluation and
approximately 25% of the non-outlier strains (randomly
selected).
Overall, 144 of the total selected 216 cases of
influenza A(H1N1)pdm09 virus infection were stud-
ied. Two cases were only studied genotypically for the
specific presence of H275Y mutation (suspected cases
1 and 3), while the remaining 142 cases (including
suspected case 2) were completely studied through
phenotypic and/or genotypic analysis.
Screening Assay for Rapid Detection of NA
H275Y Oseltamivir-Resistant Marker
Viral extraction was performed using the automat-
ed extractor EasyMag (bioMe´rieux, Linda-a-Velha,
Portugal) according to the manufacturer’s recommen-
dations. The presence of NA H275Y oseltamivir-
resistant marker was searched by real-time RT-PCR,
using a protocol kindly provided by Prof. Martin
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Curran (Public Health England [PHE], Adden-
brooke’s Hospital, Cambridge, UK). These methodolo-
gies were performed at HCC.
Quantification of H275Y Oseltamivir-Resistant
Quasi-Species
The proportion of wild-type 275H and mutant 275Y
virus in oseltamivir-resistant quasi-species was quan-
tified by pyrosequencing. This method was performed
at the PHE (Colindale, London, UK), following the
standard operating procedure in use [HPA, 2010].
Genotypic Evaluation of Virus
Susceptibility to NAIs
Genotypic evaluation was performed by NA and
HA full-length gene sequencing. RNA extraction was
performed with QIAamp Viral RNA Mini Kit (QIA-
GEN, Hilden, Germany). Sequencing methodology
and analysis included the CDC protocol recommended
by WHO [2009b] and the use of SeqMan application
of Lasergene software v.4.05 (DNASTAR, Inc., Madi-
son, WI), as described previously [Santos et al., 2011;
Giria et al., 2012]. MEGA5 software was used for
multiple sequence alignment by Clustal W method
and for mutational analysis against A/California/07/
2009 vaccine strain sequences. N1 numbering was
used for NA and the signal peptide sequence was not
considered for HA numbering. Phylogenetic analysis
included (1) determination of the best-fit model for
nucleotide substitution according to Akaike Informa-
tion Criterion, using jModelTest v.2.1.2 [Guindon and
Gascuel, 2003; Darriba et al., 2012]; and (2) construc-
tion of phylogenetic trees by maximum-likelihood
method using PhyML 3.0 software available on Sea-
view multiplatform v.4.4.0. Approximate likelihood-
ratio tests (aLRT(SH-like)) were used for measuring
branch support and subtree-pruning-and-regrafting
(SPR) and nearest-neighbor-interchange (NNI) rear-
rangement operations were considered for tree topolo-
gy improvement. NA and HA sequences of A/
California/07/2009 vaccine strain and of reference
strains were included for comparative analysis. These
sequences were retrieved from the Global Initiative
on Sharing All Influenza Data (GISAID) EpiFluTM
Database and from the National Center for Biotech-
nology Information Influenza Virus Resource. Acces-
sion numbers are provided in the phylogenetic trees,
after the sequence name. In addition, the accession
numbers from the sequences downloaded from GI-
SAID database are listed in Table II, to acknowledge
the sequence providers.
Phenotypic Evaluation of Virus
Susceptibility to NAIs
Phenotypic profiling was based on IC50 determina-
tion, using the new WHO IC50 fold-change criteria
that for influenza A viruses is: fold-change increase
<10—normal inhibition (NI); 10–100 fold-change in-
crease—reduced inhibition (RI); fold-change increase
>100—highly reduced inhibition (HRI) [Hurt et al.,
2012; WHO, 2012]. Non-outlier IC50 values from
A(H1N1) seasonal strains that circulated in Portugal
TABLE I. Epidemiological, Clinical, and Laboratorial Information Concerning the Three Cases From 2010/2011 Suspected
of Clinical Resistance Development to Oseltamivir
Case number 1 2 3
Epidemiological and clinical information
Patient
Age (years) 1 27 61
Gender Male Female Male
Underlying risk conditions Premature bronchopulmonary
dysplasia (hospitalized
since birth)
HIVþ; pregnant Not referred
Clinical disease Severe Severe with loss of
the fetus
Severe
Influenza antiviral drug treatment
Antiviral drug Oseltamivir Oseltamivir Oseltamivir
Starting date 11 days after the 1st
positive rt RT-PCR
Not referred Not referred
Evidence of failure rt RT-PCR positive after
15 days of treatment
Not referred rt RT-PCR positive after
10 days of treatment
Time between the start of antiviral
therapy and specimen collection
20 days Not possible to estimate 10 days
Clinical outcome Not referred Deceased Not referred
Other observations — Initiated treatment
with zanamivir;
from Guinea (Africa)
—
Clinical specimen laboratorial results
H275Y oseltamivir-resistant marker Not present Present (Ct¼13) Present as quasi-species
(Ct¼27 for 275Y; Ct¼28
for 275H), representing
26.2% of the virus
population
Virus strain isolated No strain isolated A/Portugal/03/2011 No strain isolated
J. Med. Virol. DOI 10.1002/jmv
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from 2004/2005 to 2008/2009 (N¼ 59 for oseltamivir;
N¼ 70 for zanamivir) [Correia et al., 2010] were used
for performing IC50 A(H1N1) lineage comparative
analysis.
Phenotypic Assay
Phenotypic testing was performed using the in-
house MUNANA-based IC50 fluorescence assay pro-
vided by PHE [HPA, 2006], as described previously in
Correia et al. [2010]. Oseltamivir carboxylate and
zanamivir were provided through a material transfer
agreement by, respectively, F.Hoffmann-La Roche
Ltd (Basel, Switzerland) and GlaxoSmithKline (Hert-
fordshire, UK).
Statistical Analysis
IC50 values were determined through point-to-point
analysis using Microsoft Office Excel 2007. Statistical
outliers were identified by determination of upper
and lower cut offs, with each one including a mild
(1.65 standard deviations [SD] above or below the
median, respectively) and an extreme (3 SD above or
below the median, respectively) level. Cut offs were
determined using Scaled Median Absolute Deviation
(SMAD) statistic method [AMC, 2001]. All outlier
strains were retested twice and the mean IC50 value
was considered for analysis. Median baseline (median
without upper and lower outliers) was used for
determination of the fold-change thresholdsRI (me-
dian 10) and HRI (median 100), and of the indi-
vidual fold-changes. Linear regression for time trend
analysis was performed using the Microsoft Office
Excel 2007 Analysis ToolPak. Cut offs, median base-
lines, fold-change thresholds and time trends were
determined separately for each time period analyzed.
Independent sample’s t and paired sample’s t-tests
were performed in SPS Statistics software v17.0 and
a P-value <0.05 was considered as statistically
significant. All phenotypic data were log-transformed
before being used for statistical analysis.
RESULTS
H275Y Mutation Analysis in Clinical Suspected
Resistant Cases
The presence of NA H275Y mutation was detected
in the clinical specimens of both cases 2 and 3,
confirming the suspicion of clinical resistance develop-
ment to oseltamivir. In the specimen of suspected case
1, only wild-type 275H virus was detected by amplifica-
tion. Detailed results are presented in Table I.
Virus Susceptibility Phenotype to NAIs
Oseltamivir. A total of 126 (88.7%; N¼ 142)
A(H1N1)pdm09 virus strains, 104 (89.7%; N¼ 116)
from the pandemic period and 23 (88.5%; N¼ 26)
from 2010/2011, exhibited an IC50 value within the
normal range to oseltamivir (range of values between
mild lower and upper cut offs—median 1.65 SD).
The IC50 values varied from 0.50 to 1.07 nM for
pandemic period strains and from 0.69 to 1.21 nM for
2010/2011 strains. The other 15 (10.6%) strains, 12
(10.3%) from the pandemic period and 3 (11.5%) from
2010/2011, were identified as statistical outliers. Nine
(6.3%) with IC50 values falling over upper cut offs, 4
at extreme level and 5 at mild level, and 6 (5.2%)
with IC50 values falling under lower cut offs (1
extreme and 5 mild). Figure 1A gives information on
oseltamivir outlier strains and IC50 fold-changes
including all IC50 values obtained for oseltamivir,
statistically analyzed and distributed by time. A/
Portugal/03/2011 (isolated from H275Y-confirmed
case 2) was the only strain exhibiting a HRI pheno-
typic profile to oseltamivir, with an 250 fold-change
increase in the IC50 value (2010/2011 RI threshold
¼ 8.85; 2010/2011HRI threshold¼ 88.50). Despite de-
tection of statistical outliers, all the other 141 strains
analyzed showed a NI phenotype to this antiviral
drug.
No apparent time grouping was observed for upper
and/or lower statistical outliers, with exception of the
two upper extreme outliers from 2009 (A/Portugal/17/
2009 and A/Portugal/82/2009), which are from 2
successive weeks (Fig. 1A). These two outlier strains
are from two A(H1N1)pdm09 positive cases closely
related at the geographic level but without epidemio-
logical link.
Considering non-outlier IC50 values, a significant
decreasing trend over time was observed among
the 2009 pandemic period values (P¼ 0.00516, R2¼
0.074172, linear regression fit). However, the very low
R2 value obtained indicates that time is a poor
predictor of IC50 variation. A significant difference was
also observed when comparing the non-outlier IC50
values from the two time periods analyzed (P¼ 0.001,
independent sample’s t-test).
Zanamivir. For zanamivir, 131 (92.3%, N¼ 142)
virus strains, 110 (94.8%; N¼ 116) from the pandemic
period and 21 (80.8%; N¼ 26) from 2010/2011, exhib-
ited an IC50 value within the normal range. Specifi-
cally, the IC50 values from pandemic period strains
varied from 0.40 to 0.99 nM and those from 2010/
2011 strains varied from 0.41 to 0.80 nM. The other
11 (7.7%) strains, 6 (5.2%) from the pandemic period
and 5 (19.2%) from 2010/2011, were identified as
statistical outliers. Six (5.2%) with IC50 values falling
over upper cut offs, one at extreme level and five at
mild level, and five (3.5%) with IC50 values falling
under lower cut offs (one extreme and four mild).
Figure 1B shows information on zanamivir outlier
strains and IC50 fold-changes including all zanamivir
IC50 values, statistically analyzed and distributed by
time. The strains A/Portugal/17/2009, A/Portugal/82/
2009, and A/Portugal/07/2011 exhibited to zanamivir
the same phenotype displayed to oseltamivir, of
upper outlier. Despite detection of statistical outliers,
all the 142 A(H1N1)pdm09 analyzed strains shared a
NI phenotypic profile to zanamivir (RI fold-change
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Fig. 1. SMAD statistical analysis of the IC50 values
obtained for the 142 A(H1N1)pdm09 virus strains analyzed
phenotypically, 116 from the pandemic period and 26 from
the 2010/2011 season, displayed by week of specimen collec-
tion, for oseltamivir (A) and zanamivir (B). The IC50 values of
virus strains from the pandemic period are coloured in black
and those of virus strains from 2010/2011 are coloured in
white (colored web version: circles represent the IC50 values
of virus strains from the pandemic period and triangles the
IC50 values of virus strains from 2010/2011). The IC50 fold-
change observed in relation to median baseline is indicated in
brackets after the strain designation.
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threshold¼ 6.20 [pandemic period] or 5.90 [2010/
2011]; HRI fold-change threshold¼ 62.0 [pandemic
period] or 59.0 [2010/2011]).
Time analysis revealed that upper outliers from
the pandemic period grouped between weeks 29 and
32 of 2009, but no epidemiological link was found
(Fig. 1B).
Concerning non-outlier IC50 values, a significant
decreasing trend over time was detected for 2009
pandemic period values (P¼ 0.00481, R2¼ 0.071277,
linear regression fit). However, as observed for oselta-
mivir, the very low R2 value prevents interpretation
of the causal relationship between these two varia-
bles. No significant difference was observed between
the values from the two time periods analyzed
(P¼ 0.374, independent sample’s t-test).
Oseltamivir and zanamivir non-outlier IC50 values
differed significantly (P¼ 0.000, paired sample’s t-
test). A significant difference was also observed for
both NAIs when comparing the non-outlier IC50
values from the A(H1N1)pdm09 strains analyzed
here with those from A(H1N1) seasonal strains that
circulated at national level from 2004/2005 to 2008/
2009 (P¼ 0.000, independent sample’s t-test) (Fig. 2).
A total of 12 A(H1N1)pdm09 virus strains (8 from
the pandemic period and 4 from 2010/2011) were
classified as upper statistical outliers for oseltamivir
and/or zanamivir and thus selected for further inves-
tigation at genotypic level. From these, only A/
Portugal/03/2011 had a known association to drug
use, having been isolated from suspected case 2
clinical specimen.
Virus Susceptibility Genotype to NAIs
NA and HA amino acid mutations found specifically
in the sequences of the 12 phenotypic upper outlier
strains are indicated and characterized in Table III.
NA-specific mutations of oseltamivir extreme outlier
strains A/Portugal/17/2019, A/Portugal/82/2009 and
A/Portugal/03/2011, have a known reduced suscepti-
bility profile (I223V and H275Y). Only A/Portugal/03/
2011 exhibited specific mutations in the HA se-
quence, harboring an N156D mutation, located in an
antigenic site. Regarding all the other oseltamivir
and/or zanamivir outlier strains, no shared mutation
or known association to a reduced susceptibility
profile were identified. In addition, approximately
half of these outliers lacked any specific mutations at
NA or HA sequences (Table III).
Mutation NA Y155H, associated with a HRI pheno-
typic profile to both NAIs in seasonal A(H1N1)
subtype [Nguyen et al., 2012], was found in the
sequence of 18 non-outlier A(H1N1)pdm09 strains
from 2009 (12.7%; 18/142), having no apparent im-
pact on NAIs phenotypic susceptibility (Fig. 3A).
Phylogenetic analysis of NA and HA nucleotide
sequences revealed two important findings: (1) lack of
nucleotide differences between the sequences of the
two upper outlier strains A/Portugal/17/2009 and A/
Portugal/82/2009, with pairwise distance calculations
confirming the 100% identity (results not shown);
and (2) no clustering among all the other outlier
strains, with outlier sequences being closely related
to non-outlier sequences from the same time period
(Fig. 3A and B).
DISCUSSION
This study comprised the analysis of A(H1N1)
pdm09 virus collected from community and from
hospitalized patients, with and without antiviral
drug treatment. Using this integrated approach it
was possible to cover the two possible settings where
influenza antiviral drug resistance or reduced suscep-
tibility can emerge—spontaneously in the community
or associated with drug use.
Oseltamivir resistance was identified for two
A(H1N1)pdm09 cases from 2010/2011, both from
oseltamivir-treated patients (suspected cases 2 and
3). The NA H275Y resistant marker was found in
viruses from both cases but for one (suspected case 3)
it was only detected in 26.2% of the clinical specimen
viral population. The fact that this percentage of
resistant virus could have been sufficient for causing
treatment failure raised questions about the minimal
percentage of resistant virus that should be consid-
ered relevant in quasi-species. For suspected case 2,
the NA H275Y mutation was identified in the entire
viral population of both clinical specimen and virus
isolate (A/Portugal/03/2011 strain). Phenotypic analy-
sis of this virus strain revealed a HRI profile to
oseltamivir (IC50¼ 219.95mM; 250 fold-change re-
duction). When compared with H275Y oseltamivir-
resistant A(H1N1) seasonal strains that circulated
previously at national level (IC50¼ 314.04–1208.84mM;
159–613 fold-change) [Correia et al., 2010], this
A(H1N1)pdm09 strain exhibited a lower IC50 value and
Fig. 2. Comparative analysis of oseltamivir and zanamivir
non-outlier IC50 values obtained for the A(H1N1)pdm09 virus
strains analyzed in this study (N¼126 oseltamivir; N¼132
zanamivir) and for seasonal A(H1N1) virus strains previously
circulating at national level, from 2004/2005 to 2008/2009
(N¼59 oseltamivir; N¼70 zanamivir).
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a similar IC50 fold-change reduction. Both results
support an over all difference between the oseltamivir
resistance levels of the H275Y viruses from the two
A(H1N1) lineages. In addition to the NA H275Y
mutation, genotypic analysis of A/Portugal/03/2011
identified HA N156D as the only other specific muta-
tion of this virus strain. HA mutations at residue 156
(N156D/S/K/T) had been described in A(H1N1)2009
variant as commonly but not exclusively associated
with virus propagation in MDCK-SIAT1 cells [WHO,
2011b]. In fact, another polymorphism at this residue
(N156K) was observed in this study for one upper
mild outlier. HA sequencing from the clinical specimen
will be essential for confirmation. Also, residue 156 is
located in the antigenic site Sa and therefore N156D
mutation could be associated with the key antigenic
Fig. 3. Phylogenetic analysis of the neuraminidase (A) and
hemagglutinin (B) full-length nucleotide sequences of the 50
A(H1N1)pdm09 virus strains evaluated genotypically, 44 from
the pandemic period and 6 from 2010/2011. Nucleotide substitu-
tion models GTRþG4 (General Time Reversible model with a 4-
category gamma distribution for rate variation among sites)
and HKY85þI (Hasegawa-Kishono-Yano model with optimized
proportion of invariable sites) were used for construction of,
respectively, NA and HA maximum-likelihood trees, as deter-
mined in jModelTest. aLRT (SH-like) branch support values
equal or higher to 0.75 are indicated in the tree. Virus strains
are symbol coded according to their phenotypic outlier classifi-
cation: ### upper extreme outlier; # upper mild outlier;  lower
mild outlier (colored web version: virus strains are colour coded
according to their phenotypic outlier classification - red: upper
extreme outlier; orange: upper mild outlier; green: lower mild
outlier; black: non-outlier). When a virus strain was outlier for
both NAIs but at different categories, the category associated
with a higher IC50 fold-change was used for strain coding.
Additionally, all strains from 2010/2011 are coloured in grey
(colored web version: all strains from 2010/2011 are marked
with the symbol #). Reference virus strains are indicated in
bold and uppercase and A/California/07/2009 vaccine strain is
additionally in italic. All indicated cluster defining amino acid
mutations were identified against vaccine strain sequence. HA
established genetic clades are based in [WHO, 2012].
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role of HA. However, a potential compensatory role for
the H275Y fitness deficit cannot be ruled out and could
be tested through in vitro replication kinetics assays
using wild-type and mutant viruses (without N156D
mutation). HA sequencing is important for the study of
antiviral drug susceptibility not only due to the poten-
tial compensatory role that HA mutations may have
but essentially due to the direct impact that HA
mutations can have on virus susceptibility. It is well-
known that HA and NA proteins work in concert
during viral entry and viral release from the cell. Thus,
if an HA mutation decreases the virus affinity for
binding cell receptors, then it could also reduce the
virus NA activity requirement for viral release and
consequently reduce the virus susceptibility to any NAI
[Zambon and Hayden, 2001].
The identification of the two H275Y oseltamivir-
resistant cases is in agreement with the sporadic
detection of resistant cases that has been observed
worldwide. Oseltamivir-resistant cases have emerged
mainly as a result of antiviral drug use and immuno-
suppressive conditions, both criteria present for sus-
pected case 2 [WHO, 2011a].
The presence of H275Y resistant marker was not
detected in the original specimen from clinical sus-
pected resistant case 1. Therefore, the evidence of
clinical failure observed can be most probably a result
of the high delay between the onset of symptoms and
the start of antiviral therapy (11 days).
Other finding of this study was the identification of
I223V mutation in the NA sequence of two A(H1N1)
pdm09 virus strains exhibiting higher IC50 values to
oseltamivir (three to four fold-change increase) and,
to a lesser extent, to zanamivir (2-fold-change
increase).These virus strains are from two A(H1N1)
pdm09 community cases from the 2009 pandemic
period. NA I223V mutation was previously associated
to a similar decreased susceptibility pattern in N1
viruses but only in one reverse genetic study [Nguyen
et al., 2012]. During surveillance activities or clinical
studies, this mutation was found in viruses with
reduced susceptibility to oseltamivir (fold-change in-
crease >10) in the A(H3N2) and B subtype/type
[Nguyen et al., 2012]. The clinical impact of I223V, as
of most NAIs reduced susceptibility-conferring muta-
tions, is still unclear. But, mutations at position 223
have previously been associated with clinical NAIs
treatment failure [van der Vries et al., 2012]. No
epidemiological link was known for the two patients
harboring the NA I223V viruses, but the identical
NA and HA sequences of the viruses and the tempo-
ral and geographic proximity of the cases, indicates a
potential relation.
The observed lack of impact of NA Y155H mutation
(HRI NAIs phenotype in A(H1N1) seasonal viruses),
in the NAIs phenotypic profile of A(H1N1)pdm09
viruses can be explained by structural differences on
the NA of A(H1N1) pandemic and seasonal variants.
These structural differences could also explain the
significantly lower IC50 values exhibited by the virus-
es from the pandemic variant. The absence of the
150-cavity, characteristic of N1 virus, in A(H1N1)
pdm09 viruses was initially indicated as the main
structural difference [Li et al., 2010]. However,
a recent study showed the presence of this cavity
in all N1 and, surprisingly, in N2 viruses, raising
new questions about NA structures [Amaro et al.,
2011].
No genetic mechanism was found for the IC50
minor increase (1.4- to 2.1-fold-change) observed for
most of oseltamivir and zanamivir upper outlier virus
strains. No shared mutation was identified and
approximately half of these virus strains lacked any
specific mutations at NA or HA sequences. Addition-
ally, the majority of the specific mutations identified
probably derived from the key antigenic role of these
two glycoproteins, given their location in antigenic
sites or by creating potential N-glycosylation sites
that may prevent accessibility and recognition of
antigenic sites by antibodies [Vigerust et al., 2007].
Other specific mutations, positioned in the stalk
region of the protein, are most likely not related with
antiviral susceptibility. Whole genome sequencing
of upper outlier strains is being performed in order
to find if mutations located in the other genome
segments can be contributing for the IC50 minor
increases observed. The understanding of these minor
increases is one of the major current challenges in
influenza antiviral drug susceptibility evaluation.
A(H1N1)pdm09 viruses were more susceptible to
zanamivir than to oseltamivir. This drug-specific
variation is characteristic of N1 viruses and results
from differences in the intrinsic chemical properties
of the two NAIs [Ferraris and Lina, 2008]. The
chemical similarity that zanamivir exhibits to the
natural substrate of NA (sialic acid) could explain
the different phenotypic results obtained for this
drug [van der Vries et al., 2012]. This includes the
lack of significant differences between the IC50 values
from the two time periods analyzed and the lower
impact of NA I223V mutation on virus susceptibility
(lower IC50 fold-change). Regarding oseltamivir, the
two NA-specific mutations of 2010/2011 virus strains
—N369K and V241I, may have contributed for the
significantly higher IC50 values obtained during that
season. Computational analysis showed that both
mutations improve NA stability of H275Y oseltami-
vir-resistant virus and experimental studies showed
that N369K increases NA surface expression and
activity of this resistant variant [Hurt et al., 2012].
However, the unequal size of the two time period
datasets (N¼ 116 for the pandemic period and N¼ 26
for 2010/2011) may also be contributing for this IC50
temporal difference.
The results obtained in this study may contribute
to a better understanding of the currently challeng-
ing phenotype–genotype relationship. In addition, all
national data presented here may contribute to the
global assessment of A(H1N1)pdm09 virus suscepti-
bility profile and baseline level to NAIs.
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